Research article · 15 Apr 2026
Conference abstractPublished 15 Oct 2018
Urate-lowering therapy ameliorates kidney function in type 2 diabetes patients with hyperuricemia
Ueno Internal Medicine and Diabetes Clinic, Japan
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Objective: Hyperuricemia often causes kidney dysfunction which increases serum urate, forming a vicious cycle in the kidney. In this study, urate-lowering therapy was demonstrated in type 2 diabetes patients with hyperuricemia to evaluate the effect on diabetic nephropathy. Methods: Type 2 diabetes patients with hyperuricemia (n=34) were treated by urate-lowering drugs. Serum urate levels, estimated glomerular filtration rate (eGFR), blood pressure, HbA1c, and urinary albumin-excretion rate (UAER) were measured for 52 weeks. The parameters at the end point when serum urate decreased to below 6.0 mg/dL and at 52 weeks were compared to the initial levels at week 0. Results: Serum urate level decreased to the end point in all patients and was maintained at under 6.0 mg/dL throughout the observation period. eGFR significantly increased at the end point and also at 52 weeks. Overall UAER did not change after 52 weeks; however, the treatment decreased UAER significantly in patients with no microalbuminuria. There was a negative relationship between the change of serum urate levels and the change of eGFR, and a negative relationship between the baseline UAER and the change of UAER when patients with macroalbuminuria were excluded. There were no changes in HbA1c levels and blood pressure before and after the treatment. Conclusion: There were significant improvements in kidney function by lowering serum urate levels to under 6.0 mg/dL and the effect was maintained for at least 52 weeks. This treatment may be one strategy to slow the progression of nephropathy in type 2 diabetic patients with hyperuricemia.
Subjects
Nephrology & UrologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Nephrology & Therapeutics.
Brief report · 30 Mar 2026
Renal Fibrosis: Targeting Pathways For New Therapies
Brief report · 30 Mar 2026
SGLT2 Inhibitors: A New Era for Diabetic Kidney Disease
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Nephrology & Therapeutics
- SubjectNephrology & Urology
- BylineArticles whose byline prints “Naohiko Ueno”

